Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with…

Read this Press Release: Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update

New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with…

Read this Press Release: New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership